Estradiol

Estradiol (E2) is the most potent and biologically active form of estrogen, produced primarily by the ovaries in premenopausal women and in smaller amounts by the adrenal glands and fat tissue in both sexes. In men, estradiol is produced through aromatization of testosterone — a process that occurs mainly in fat tissue and is critical for bone health, brain function, and cardiovascular protection.

In women, the dramatic decline of estradiol during menopause (typically ages 45–55) triggers a cascade of accelerated aging: rapid bone loss (up to 3–5% of bone density per year in the first 5 years), increased cardiovascular risk (women lose their premenopausal cardiovascular advantage), cognitive changes, and loss of connective tissue integrity. The timing of hormone replacement therapy (HRT) matters enormously — the 'timing hypothesis' suggests that HRT initiated within 10 years of menopause or before age 60 provides cardiovascular protection, while later initiation may not.

In men, estradiol is a Goldilocks hormone — both too high and too low are problematic. Very low estradiol (often seen with aggressive aromatase inhibitor use) leads to bone loss, joint pain, mood disturbance, and adverse lipid changes. Elevated estradiol (common in obesity, as more testosterone is aromatized in fat tissue) is associated with gynecomastia, water retention, and potentially increased cardiovascular risk. The optimal range for men is approximately 20–30 pg/mL.